PMV Pharmaceuticals Inc. (NASDAQ: PMVP) is making moves in the fight against ovarian cancer. On Monday, the company shared interim data from its Phase 2 PYNNACLE trial for rezatapopt, an investigational treatment for the disease. The results are promising enough that the company is gearing up to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval.
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push
MarketDash
PMV Pharmaceuticals reports 46% ORR in Phase 2 trial for ovarian cancer drug rezatapopt. NDA submission planned for Q1 2027.
Get PMV Pharmaceuticals Alerts
Weekly insights + SMS alerts
Efficacy Highlights
The interim data, collected up to May 14, 2026, focuses on patients with platinum-resistant or refractory ovarian cancer who carry the TP53 Y220C mutation. Among the 76 patients evaluated, the drug achieved a 46% overall response rate (ORR), including four confirmed complete responses and 29 confirmed partial responses.
Rezatapopt also demonstrated a median duration of response of 10.0 months, suggesting the drug's effects are not just quick but lasting. The safety profile looks favorable too, with mostly Grade 1 and 2 treatment-related adverse events and a low 5% discontinuation rate tied to those events.
Regulatory Path
The company plans to present a comprehensive update on all PYNNACLE Phase 2 cohorts at an upcoming medical conference in the fourth quarter of 2026. Following a recent FDA meeting, PMV Pharmaceuticals received feedback supporting its strategy to seek accelerated approval for rezatapopt. The company intends to submit the NDA in the first quarter of 2027.
Funding The Future
In related news, PMV Pharmaceuticals priced a public offering expected to generate approximately $50.8 million in gross proceeds. The offering includes shares of common stock, pre-funded warrants, and accompanying warrants, with a combined public offering price of $1.21 per share and warrant combination. This financial move supports the company's ongoing research and anticipated regulatory submissions.
PMVP Price Action: PMV Pharmaceuticals shares were down 10.74% at $1.08 during premarket trading on Tuesday, according to market data.
More News
Stock Market Today: S&P 500, Dow Futures Slide as Trump Declares Iran 'Totally Defeated', Brent Tops $92 — CBRS, PXS, PANW, DELL in Focus
Treasury Yields Hit 4.8%: The Bond Market's Message to Washington
Broadcom Stock Dips Ahead of Earnings as VMware AI Push Takes Center Stage
Peter Schiff Warns of 8% Treasury Yields and 10% Mortgage Rates as Bond Market Enters 'Bear Market'
Trump's Venezuela Oil Deal: A Refining Reality Check
NVIDIA's New Move: Getting Paid Even When You Don't Buy Its Chips
Trump Jr.-Linked Firm Leads $1B Polymarket Round, Valuing Platform at $21B
Treasury Secretary Warns Iran's Economy Could Collapse 'Within Weeks or Months' as Sanctions Bite
Get PMV Pharmaceuticals Alerts
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
Featured Articles
View all newsStock Market Today: S&P 500, Dow Futures Slide as Trump Declares Iran 'Totally Defeated', Brent Tops $92 — CBRS, PXS, PANW, DELL in Focus
By MarketDash
September 1, 2026
Treasury Yields Hit 4.8%: The Bond Market's Message to Washington
By MarketDash
September 1, 2026
Broadcom Stock Dips Ahead of Earnings as VMware AI Push Takes Center Stage
By MarketDash
September 1, 2026
Peter Schiff Warns of 8% Treasury Yields and 10% Mortgage Rates as Bond Market Enters 'Bear Market'
By MarketDash
September 1, 2026
Trump's Venezuela Oil Deal: A Refining Reality Check
By MarketDash
September 1, 2026
NVIDIA's New Move: Getting Paid Even When You Don't Buy Its Chips
By MarketDash
September 1, 2026
Trump Jr.-Linked Firm Leads $1B Polymarket Round, Valuing Platform at $21B
By MarketDash
September 1, 2026
Treasury Secretary Warns Iran's Economy Could Collapse 'Within Weeks or Months' as Sanctions Bite
By MarketDash
September 1, 2026